Description
Screening for dihydropyrimidine dehydrogenase deficiency to prevent severe fluoropyrimidine-associated toxicity
- You cannot add another "Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer" to your cart. View cart
Article: Screening for dihydropyrimidine dehydrogenase deficiency to prevent severe fluoropyrimidine-associated toxicity
€3.03
Related products
-
Article: Highlights in breast cancer
€3.03 Add to cart -
Article: Highlights in respiratory oncology
€3.03 Add to cart -
Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer
€3.03 Add to cart -
1 year subscription print edition of the Belgian Journal of Hematology (BJH)
€209.83 Add to cart
